Bristol-Myers Squibb Company
BMY
$59.01
-$1.27-2.11%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Net Income | -211.50% | -187.60% | -182.14% | -184.09% | 26.84% |
Total Depreciation and Amortization | -1.99% | 4.17% | 0.71% | -1.99% | -4.99% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 780.84% | 711.77% | 533.44% | 645.94% | -53.73% |
Change in Net Operating Assets | 142.32% | 112.05% | 69.38% | 88.97% | 14.13% |
Cash from Operations | 9.60% | 16.18% | 19.52% | 12.27% | 6.08% |
Capital Expenditure | -3.23% | 2.04% | -7.79% | -6.30% | -8.14% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -1,766.64% | -3,075.43% | -513.71% | -439.11% | 72.73% |
Divestitures | 20.90% | -26.98% | -26.16% | -31.68% | -30.34% |
Other Investing Activities | 174.82% | -94.35% | -107.02% | -111.38% | -127.20% |
Cash from Investing | -830.37% | -8,623.48% | -1,512.86% | -1,487.64% | -116.10% |
Total Debt Issued | 258.45% | 5,481.57% | 6,574.59% | 7,142.86% | -27.21% |
Total Debt Repaid | -46.86% | -325.39% | -12.48% | 67.69% | 65.02% |
Issuance of Common Stock | -- | 1,150.00% | -- | -- | -- |
Repurchase of Common Stock | -- | 100.00% | 3.75% | -50.88% | 35.57% |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -2.51% | -1.61% | -1.88% | -2.48% | -2.37% |
Other Financing Activities | -- | -148.60% | -133.16% | -100.89% | -100.00% |
Cash from Financing | 154.45% | 156.76% | 149.40% | 157.65% | 44.49% |
Foreign Exchange rate Adjustments | -404.44% | 41.94% | -179.41% | 55.17% | 236.36% |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -153.42% | 183.55% | 16.02% | 108.10% | 143.96% |